In The News
-
January 25, 2012
Five Big Drugs for 2012
These medications could boost the fortunes of companies like Pfizer, Gilead Sciences and Bristol-Myers Squibb.
-
December 22, 2011
Three key antipsychotics lose patent protection
State Medicaid programs, patients to save as major atypical meds “go generic”
-
November 8, 2011
Dabigatran's First A Fib Year Starts Warfarin's Decline
For decades, physicians and patients bemoaned the problems and inconveniences of warfarin to prevent strokes caused by atrial fibrillation. A simpler, easier oral anticoagulant was what people wanted and what drove drug companies to try to find alternatives.
-
November 7, 2011
MS pipeline flowing, but niche remains for neuroprotection
For decades, people with multiple sclerosis have injected themselves daily with immunosuppressant drugs for lack of a better option, in hopes of mitigating the disease's neurodegenerative effects. But newly designed oral therapies for the disorder have proliferated over the past few years, foretelling a future with fewer pricks.
-
October 25, 2011
BioReference's genetic-testing business has new tool for detecting rare diseases
Scientists at GeneDx, a subsidiary of Elmwood Park-based BioReference Labs, develop a new genetic test capable of analyzing a patient’s DNA more comprehensively than existing technology. The new test provides doctors with a critical new tool for detecting rare diseases.
-
October 7, 2011
The Widening of the Obese Market: Companies Cash In on Growing Waistlines
Nearly 150 million people in the U.S. are obese or overweight, according to market research statistics. With little evidence of this demographic slimming down, experts say the obesity market is rife with opportunities for businesses to cash in.
-
October 3, 2011
Targacept depression drug: high risk, high reward
Targacept Inc, a small drugmaker that began life inside the bowels of R.J. Reynolds Tobacco Co, has for years been using its understanding of nicotine to develop experimental treatments for depression, schizophrenia and smoking cessation.
-
September 30, 2011
What’s new copycat?
Blockbuster biologics aren’t immune to patent expiries and a raft of companies are ready to pounce with copycat versions. But biosimilars aren’t generics – they have their own unique set of problems
-
September 27, 2011
Novartis To File Lung Drug In Europe After Strong Trials
Novartis AG (NVS) on Tuesday said it will file experimental lung medicine NVA237 with European regulators in the wake of strong trial data, raising the odds that its lung-drug franchise will develop into a multi-billion-dollar business.
-
September 19, 2011
Analysis: New drugs drive prostate cancer market
Options for treating prostate cancer are expanding with the advent of novel, and more expensive, medicines, with key data expected soon for what could be one of the biggest new drugs.
Decision Resources Group companies include: